Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma
Authors:
Open Access
- 1 May 2008
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 3 (5) , 527-529
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Impact of Primary or Secondary MutationsClinical Lung Cancer, 2006
- Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib TrialsJournal of Clinical Oncology, 2005
- Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With ErlotinibJournal of Clinical Oncology, 2005
- TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future DirectionsJournal of Clinical Oncology, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Comparison of K‐ras point mutation distributions in intraductal papillary‐mucinous tumors and ductal adenocarcinoma of the pancreasInternational Journal of Cancer, 2004
- Genetic heterogeneity of single disseminated tumour cells in minimal residual cancerThe Lancet, 2002
- Heterogeneity of p53 mutational status in the superficial spreading type of early gastric carcinomaGastric Cancer, 2001